Details for Patent: 11,771,733
✉ Email this page to a colleague
Which drugs does patent 11,771,733 protect, and when does it expire?
Patent 11,771,733 protects QBRELIS and is included in one NDA.
This patent has ten patent family members in eight countries.
Summary for Patent: 11,771,733
| Title: | Lisinopril formulations |
| Abstract: | Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction. |
| Inventor(s): | Gerold L. Mosher, David W. Miles |
| Assignee: | Azurity Pharmaceuticals Inc |
| Application Number: | US17/507,144 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; |
Drugs Protected by US Patent 11,771,733
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | 11,771,733 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,771,733
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3003274 | ⤷ Start Trial | |||
| China | 108472252 | ⤷ Start Trial | |||
| China | 112972370 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
